# A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations

> **NCT05560334** · PHASE2 · UNKNOWN · sponsor: **Tianjin Medical University Cancer Institute and Hospital** · enrollment: 20 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Pemigatinib Pill

## Key facts

- **NCT ID:** NCT05560334
- **Lead sponsor:** Tianjin Medical University Cancer Institute and Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-09-08
- **Primary completion:** 2024-09-08
- **Final completion:** 2025-09-08
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2022-09-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05560334

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05560334, "A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05560334. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*